Literature DB >> 17417790

Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H.

Mwe Mwe Chao1, John E Levine, James L Ferrara, Laura Cooling, Kenneth R Cooke, Raymond J Hutchinson, Gregory A Yanik.   

Abstract

Immune-mediated hemolytic anemia is a well-recognized complication of hematopoietic stem cell transplantation. We report on a 6-year-old boy with X-linked adrenoleukodystrophy who developed severe delayed alloimmune hemolytic anemia associated with immune-mediated neutropenia and thrombocytopenia following major ABO incompatible unrelated cord blood transplantation. The patient's cytopenias were refractory to treatment with corticosteroids, cyclosporine, intravenous immune globulin, rituximab, and pentostatin. After one course of Campath-1H his hematologic parameters normalized, suggesting that the compound may be an effective therapy for complex immunohematologic disorders complicating hematopoietic stem cell transplantation. The case also emphasizes the importance of T-cells in transplant associated immune cytopenias. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17417790     DOI: 10.1002/pbc.21187

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Annalisa Condorelli; Maddalena Casale; Paola Giordano; Lucia D Notarangelo; Piero Farruggia; Fiorina Giona; Agostino Nocerino; Silvia Fasoli; Maria L Casciana; Maurizio Miano; Fabio Tucci; Tommaso Casini; Paola Saracco; Wilma Barcellini; Alberto Zanella; Silverio Perrotta; Giovanna Russo
Journal:  Blood Transfus       Date:  2018-04-13       Impact factor: 3.443

2.  Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.

Authors:  V Bhatt; L Shune; E Lauer; M Lubin; S M Devlin; A Scaradavou; R Parameswaran; M A Perales; D M Ponce; S Mantha; N A Kernan; J N Barker
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

3.  The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant.

Authors:  Ibrahim Ahmed; Jun Teruya; Cristina Murray-Krezan; Robert Krance
Journal:  Pediatr Transplant       Date:  2015-03-23

Review 4.  Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.

Authors:  Geoffrey D E Cuvelier; Michelle Schoettler; Nataliya P Buxbaum; Iago Pinal-Fernandez; Marc Schmalzing; Jörg H W Distler; Olaf Penack; Bianca D Santomasso; Robert Zeiser; Klemens Angstwurm; Kelli P A MacDonald; W Taylor Kimberly; Naomi Taylor; Ervina Bilic; Bernhard Banas; Maike Buettner-Herold; Namita Sinha; Hildegard T Greinix; Joseph Pidala; Kirk R Schultz; Kirsten M Williams; Yoshihiro Inamoto; Corey Cutler; Linda M Griffith; Stephanie J Lee; Stefanie Sarantopoulos; Steven Z Pavletic; Daniel Wolff
Journal:  Transplant Cell Ther       Date:  2022-05-31

5.  Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience.

Authors:  J Sanz; M Arango; N Carpio; P Montesinos; F Moscardó; G Martín; F López; I Jarque; I Lorenzo; J de la Rubia; P Solves; B Boluda; C Salazar; C Cañigral; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

6.  Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.

Authors:  Wilma Barcellini; Bruno Fattizzo; Anna Zaninoni
Journal:  J Blood Med       Date:  2019-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.